Mineral supplements tied to better insulin control in women with PCOS

Polycystic ovary syndrome affects many women of reproductive age and frequently brings insulin resistance, which disturbs both glucose and fat metabolism and shapes longer-term metabolic risk. Mineral supplements such as magnesium, chromium, zinc and selenium are inexpensive, widely available and often promoted for metabolic health. Individual trials in PCOS have tested them, but singly and at small scale, which makes the overall picture hard to judge. This review set out to pool the randomised evidence and ask whether minerals genuinely improve insulin resistance, blood sugar and lipid profiles in this group.

The reviewers ran a systematic search across four databases for randomised controlled trials comparing mineral supplements against placebo in women with PCOS, covering magnesium, chromium, zinc, selenium and chromium picolinate. Eleven trials involving 618 women met the inclusion criteria. The risk of bias in each trial was assessed with the Cochrane Risk of Bias 2 tool, and the data were pooled using both fixed-effect and random-effects models to estimate the impact on glycaemic and lipid measures.

Mineral supplementation was associated with significant reductions in fasting blood glucose, fasting insulin and HOMA-IR, the standard index of insulin resistance, and these glycaemic effects were the most consistent findings. Total cholesterol and triglycerides also fell significantly. The lipid picture was not uniformly positive, however: HDL, often called the good cholesterol, showed a small but statistically significant reduction, and LDL cholesterol did not change at all. The authors describe the lipid effects overall as mixed.

A consistent glycaemic signal across eleven trials is noteworthy for a condition in which insulin resistance drives much of the trouble. The main limitation is that several different minerals were pooled together, so the analysis cannot say which one, alone or in combination, is responsible, nor at what dose or for how long. The authors call for larger, well-designed trials to clarify long-term benefits and optimal supplementation strategies, which is the right reading of an encouraging but unfinished evidence base.

For women managing PCOS, this is worth knowing: common, inexpensive minerals showed a consistent association with better insulin and glucose measures across pooled trials. It is equally worth knowing what the analysis cannot tell you, namely which mineral matters and at what dose, and that one lipid marker, HDL, nudged the wrong way. It is information to bring to a conversation with a clinician rather than a verdict on any particular bottle on the shelf.